PRPO Stock Summary and Trading Ideas (Precipio | NASDAQ:PRPO)

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. It focuses on improving cancer diagnostics, particularly hematologic malignancies. Its objective is to enhance diagnostic accuracy and accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, and Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division and the Products Division.

Precipio trades on the NASDAQ stock market under the symbol PRPO.

As of April 28, 2026, PRPO stock price climbed to $31.82 with 84,575 million shares trading.

PRPO has a beta of 0.39, meaning it tends to be less sensitive to market movements. PRPO has a correlation of 0.01 to the broad based SPY ETF.

PRPO has a market cap of $55.75 million. This is considered a Micro Cap stock.

In the last 3 years, PRPO traded as high as $32.40 and as low as $3.90.

The top ETF exchange traded funds that PRPO belongs to (by Net Assets): VXF, VTI, DFSU, DFAS, DCOR.

PRPO has outperformed the market in the last year with a price return of +427.7% while the SPY ETF gained +30.6%. PRPO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +29.9% and +13.4%, respectively, while the SPY returned +2.6% and +3.7%, respectively.

PRPO support price is $29.07 and resistance is $32.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRPO shares will trade within this expected range on the day.